Physician profile
Fadee Kutom
NPI 1245717909
$4,253.11
in general payments reported to CMS, 2019-2025
14 companies · $466 in 2025
The $466 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.17 · 2020: $23.35 · 2022: $143 · 2023: $188 · 2024: $3,371 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $790 · Food and Beverage: $734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $790.44 |
| Food and Beverage | $734.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,546.32 | 2023-2025 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $267.84 | 2022-2023 | Arexvy |
| Inspire Medical Systems, INC. | $146.81 | 2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $76.81 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $33.72 | 2019-2025 | Breztri |
| Chiesi USA, INC. | $31.74 | 2025 | Cleviprex, Kengreal |
| Abiomed | $27.51 | 2025 | |
| Amgen INC. | $25.21 | 2025 | Tezspire |
| Abbvie INC. | $23.35 | 2020 | |
| Electromed, INC. | $18.34 | 2025 | Smartvest |
| Pfizer INC. | $15.91 | 2019 | |
| Gilead Sciences, INC. | $14.85 | 2019 | |
| Horizon Therapeutics Plc | $14.07 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.63 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadee Kutom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.